The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Psychopharmacology

• Publication date

  2010-01-19

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00213-009-1771-5PMID 20084367PMCID PMC2866021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats

  2009cited by this paper
• Discriminative Stimulus Effects of 1-(2,5-Dimethoxy-4-Methylphenyl)-2-Aminopropane in Rhesus Monkeys: Antagonism and Apparent pA2 Analyses

  2009influential reference
• Unconditioned Behavioral Effects of the Powerful κ-Opioid Hallucinogen Salvinorin A in Nonhuman Primates: Fast Onset and Entry into Cerebrospinal Fluid

  2009influential reference
• Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

  2009cited by this paper
• Salvia Divinorum Use among a College Student Sample

  2008cited by this paper
• Legally High? Legal Considerations of Salvia divinorum

  2008cited by this paper
• Internet access to Salvia divinorum: implications for policy, prevention, and treatment.

  2008cited by this paper
• Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans

  2008cited by this paper
• Discriminative Stimulus Effects of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane in Rhesus Monkeys

  2008cited by this paper
• College student use of Salvia divinorum.

  2008cited by this paper
• The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.

  2007cited by this paper
• Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

  2007cited by this paper
• Effects of Salvinorin A, a κ-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High κ-Receptor Homology to Humans

  2007cited by this paper
• Pattern of use and subjective effects of Salvia divinorum among recreational users.

  2006cited by this paper
• Pharmacokinetics of the plant‐derived κ‐opioid hallucinogen salvinorin A in nonhuman primates

  2005cited by this paper
• Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

  2005cited by this paper
• Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

  2005cited by this paper
• Comparison of Pharmacological Activities of Three Distinct κ Ligands (Salvinorin A, TRK-820 and 3FLB) on κ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo

  2005cited by this paper
• Synthesis and evaluation of novel peripherally restricted κ-opioid receptor agonists

  2005cited by this paper
• Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.

  2005cited by this paper
• Ketamine-induced distractibility: An oculomotor study in monkeys.

  2005cited by this paper
• The plant-derived hallucinogen, salvinorin A, produces κ-opioid agonist-like discriminative effects in rhesus monkeys

  2004influential reference
• Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys

  2004cited by this paper
• The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

  2004cited by this paper
• Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional Considerations

  2004cited by this paper
• Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates.

  2003cited by this paper
• Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist

  2002cited by this paper
• Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

  2002cited by this paper
• End-tidal carbon dioxide monitoring during procedural sedation.

  2002cited by this paper
• Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.

  2001cited by this paper
• Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys

  2000cited by this paper
• Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction.

  1999cited by this paper
• Effects of E-2078, a stable dynorphin A(1–8) analog, on sedation and serum prolactin levels in rhesus monkeys

  1999influential reference
• Quadazocine decreases responding reinforced by ethanol, sucrose, and phencyclidine fluid deliveries in rhesus monkeys: comparison to naltrexone’s effects

  1999cited by this paper
• Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.

  1999cited by this paper
• Discriminative Stimulus Effects of the Nonpeptidic δ-Opioid Agonist SNC80 in Rhesus Monkeys

  1999cited by this paper
• Long-Lasting Psychotomimetic Consequences of Repeated Low-Dose Amphetamine Exposure in Rhesus Monkeys

  1999cited by this paper
• Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

  1998cited by this paper
• Differentiation of Kappa Opioid Agonist-Induced Antinociception by Naltrexone Apparent pA 2 Analysis in Rhesus Monkeys 1 , 2

  1998cited by this paper
• The effects of spiradoline (U‐62066E), a κ‐opioid receptor agonist, on neuroendocrine function in man

  1997cited by this paper
• Discriminative stimulus effects of nalbuphine in rhesus monkeys.

  1996cited by this paper
• Effects of the NMDA antagonist, dizocilpine, in various drug discriminations: characterization of intermediate levels of drug lever selection

  1995cited by this paper
• Salvia divinorum and salvinorin A: new pharmacologic findings.

  1994cited by this paper
• Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities.

  1994cited by this paper
• Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.

  1993cited by this paper
• Validity and Reliability of the Observer's: Assessment of Alertness/Sedation Scale Study with Intravenous Midazolam

  1990cited by this paper
• Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys.

  1989cited by this paper
• Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys.

  1989cited by this paper
• ICI 204448: a κP‐opioid agonist with limited access to the CNS

  1989cited by this paper
• ICI 204448: a kappa-opioid agonist with limited access to the CNS.

  1989cited by this paper
• Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects.

  1987cited by this paper
• Psychotomimesis mediated by kappa opiate receptors

  1986cited by this paper
• Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines, and mescaline in rodents, dogs, and monkeys.

  1978cited by this paper
• PSYCHOPHARMACOLOGY

  1957cited by this paper

• Psychedelic studies in nonhuman primates: Past and future

  2025cites this paper
• The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys.

  2022cites this paper
• A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review

  2022cites this paper
• Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.

  2021cites this paper
• Therapeutic Use of Hallucinogens

  2021cites this paper
• Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

  2020cites this paper
• Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys

  2020cites this paper
• Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study

  2019cites this paper
• Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

  2018cites this paper
• Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans

  2018cites this paper
• Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents

  2018cites this paper
• Neuropathic and inflammatory antinociceptive effects and electrocortical changes produced by Salvia divinorum in rats.

  2017cites this paper
• The Kappa Opioid Agonist , Salvinorin A , Attenuates Locomotor Effects of Morphine but not Morphine-Induced Conditioned Place Preference

  2017cites this paper
• The Widely Available Hallucinogenic Plant Salvia divinorum and Its Main Component, Salvinorin A

  2016cites this paper
• Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans

  2016cites this paper
• Clinical applications of hallucinogens: A review.

  2016cites this paper
• Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.

  2016cites this paper
• The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

  2015cites this paper
• Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

  2015cites this paper
• Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

  2015cites this paper
• Purificación, caracterización e identificación de salvinorina a en salvia divinorum.

  2015cites this paper
• Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat

  2014cites this paper
• Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

  2014influential citation
• Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug

  2013cites this paper
• 2012 David W. Robertson Award for Excellence in Medicinal Chemistry: Neoclerodanes as Atypical Opioid Receptor Ligands⊥

  2013cites this paper
• A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys.

  2013influential citation
• Investigations Of Salvinorin A: Synthetic Isolation, Quantification, And In Vivo Characteristics

  2013cites this paper
• Neoclerodanes as atypical opioid receptor ligands.

  2013cites this paper
• LC-MS/MS quantification of salvinorin A from biological fluids.

  2013cites this paper
• Characterization of human TRPA1 and TRPV1 channels in response to naturally occurring defensive compounds

  2013cites this paper
• Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.

  2013cites this paper
• The K appa Opioid Agonist, Salvinorin A, Att enuates Locomotor Effec ts of Morphine but not Morphine-Induced Conditioned Place Preference

  2012cites this paper
• Investigation of Natural Product Scaffolds for the Development of Opioid Receptor Ligands

  2012cites this paper
• Behavioral Effects and Central Nervous System Levels of the Broadly Available κ-Agonist Hallucinogen Salvinorin A Are Affected by P-Glycoprotein Modulation In Vivo

  2012cites this paper
• The Action of Plants and their Constituents on the Central Nervous System

  2012cites this paper
• The dynorphin/j-opioid receptor system and its role in psychiatric

  2012cites this paper
• Acute and post-acute behavioral and psychological effects of salvinorin A in humans

  2011cites this paper
• Pharmacological activity of Salvinorin A, the major component of Salvia divinorum

  2011cites this paper
• Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A

  2011influential citation
• Endogenous opiates and behavior: 2010.

  2011cites this paper
• Investigating the Effects of Novel Kappa Opioid Receptor Agonists on the Dopamine Transporter

  2011cites this paper
• Neuropharmacology of the Naturally Occurring κ-Opioid Hallucinogen Salvinorin A

  2011cites this paper
• Learning and Memory Impairment Induced by Salvinorin A, the Principal Ingredient of Salvia divinorum, in Wistar Rats

  2011cites this paper
• The dynorphin/κ-opioid receptor system and its role in psychiatric disorders

  2011cites this paper
• Behavioural Pharmacology of Novel Kappa Opioid Compounds

  2011cites this paper
• The Synthesis and Pharmacological Evaluation of Salvinorin A Analogues as Opioid Receptor Probes

  2011cites this paper
• Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.

  2010cites this paper
• Preparation of neoclerodane diterpenes as probes for the opioid receptor system

  2010cites this paper